TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Previously untreated follicular stage III or IV non-Hodgkin's lymphoma At least one measurable mass~PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: WHO 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Alkaline phosphatase and bilirubin less than 2.5 times upper limit of normal (ULN) (unless clearly related to NHL) Renal: Creatinine and BUN less than 2.5 times ULN (unless clearly related to NHL) Cardiovascular: No severe cardiac disease (e.g. severe heart failure requiring treatment or cardiac ejection fraction less than 45%) Neurologic: No neurologic disease Pulmonary: No pulmonary disease Other: Not pregnant No prior malignancies except nonmelanoma skin cancer or carcinoma in situ of the cervix Not HIV positive No psychiatric or metabolic disease~PRIOR CONCURRENT THERAPY: See Disease Characteristics No concurrent immunotherapeutic drugs, chemotherapy, or radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Immunization Distress (RID)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children, ages 4-6 years, scheduled to receive the standard pre-kindergarten immunizations. This consists of two injections: the Dtap (diphtheria, tetanus, acellular pertussis) and IPV (injectable polio vaccine) or three injections: DTAP, IPV and MMR (measles, mumps, rubella);~* With or without prior exposure to ST at PMG;~* English speaking subject and parents~Exclusion Criteria:~* Acute concurrent illness;~* Invasive procedures such as cannulation, venipuncture or urinary VCG in the preceding 6 months;~* Hospitalization or ED visit, within the prior 6 months;~* Chronic medical conditions requiring repeated painful interventions;~* Inability to respond age appropriately with verbal and written answers to questions, to pain scale measures, or to questionnaires;~* Refusal to be videotaped.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- Standard technique (Type: ACTIVE_COMPARATOR): Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
- Parent participation technique (Type: EXPERIMENTAL): The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nitrous Oxide Vasodilation Healthy Adult Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult volunteers.~* 19 years or older (inclusive)~* English speaking.~Exclusion Criteria:~* ASA class III or greater;~* History of, or suspected, difﬁcult airway based on physical exam, facial dysmorphism or syndrome~* Any condition in which air may be trapped in a body cavity. These include, but are not limited to:~Pneumothorax or chest injury, concurrent acute asthma exacerbation, middle ear occlusion, intestinal obstruction, ileus, or abdominal distension, sinusitis or maxillofacial injuries with potential for trapped gas, recent intraocular surgery or penetrating globe injury, air embolus, severe bullous emphysema (consider in patients with cystic ﬁbrosis), history of craniotomy in previous three weeks~* Pregnancy (1st and 2nd trimester)~* Increased intracranial pressure, impaired level of consciousness, or head injury~* Known Vitamin B12 deﬁciency~* Known MTHFR Deﬁciency (Inborn error of metabolism)~* History of bleomycin administration (note that the oxygen component of N2O administration is what interacts with bleomycin to cause pulmonary toxicity)~* Intoxication with alcohol or other drugs~* Any condition in which patient may be catecholamine-depleted (e.g. septic shock)~* Recent history of altered mental status~* Pulmonary hypertension~* Congestive heart failure.~* Trainees, including students, residents, and fellows, working in the pediatric emergency department.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 50% Nitrous oxide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of the Infusion of Donor Plasma in COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* SARS CoV 2 infection, confirmed by PCR or technique of similar specificity.~* Symptom onset, or positive PCR (whichever comes first) within 7 days (168 hours) prior to planned plasma infusion.~* 65 years of age or older.~* All patients, or the guardian appointed by the judge, in the case of recognized judicial incapacity, must sign the informed consent document.~Exclusion Criteria:~* Less than 65 years of age~* Symptom onset, or positive PCR (whichever comes first), more than 7 days (168 hours) prior to planned plasma infusion.~* Severe dementia, or other significant comorbidity, that generates a serious deterioration of the baseline functional status, with a life expectancy of less than 6 months.~* Participation in another clinical trial or study.~* History of allergy to amotosalen or psoralens

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Treatment in the intervention group:~Infusion of 300 cc of convalescent donor plasma from COVID 19, administered within more than 168 hours from the onset of symptoms Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment.
- Control (Type: ACTIVE_COMPARATOR): Treatment in the control group:~For the study to be blind, the infusion of non-convalescent donor plasma, obtained before the start of the epidemic, is required to guarantee the absence of anti-COVID antibodies in the plasma of the control group.~Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Male or female patient ≥ 18 years of age~2. Histologically or cytologically confirmed non-squamous NSCLC~3. EGFR-mutation positive patients must have progressed on or had intolerance to an EGFR small molecule tyrosine kinase inhibitor~4. Patients whose tumors harbor an anaplastic lymphoma kinase (ALK) translocation must have progressed on or had intolerance to an ALK inhibitor;~5. No prior adjuvant chemotherapy within 1 year of the first treatment day if there is recurrent disease~6. At least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1~7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and minimum life expectancy of ≥ 3 months~8. Adequate bone marrow, renal and liver function~Main Exclusion Criteria:~1. Histologic evidence of predominantly squamous cell NSCLC~2. Brain metastasis and/or leptomeningeal disease (known or suspected)~3. Peripheral neuropathy \> CTCAE grade 1~4. Possibility of a curative local treatment (surgery and/or radiotherapy)~5. Previous chemotherapy except adjuvant treatment with progression of disease documented ≥ 12 months after end of adjuvant treatment~6. Having received treatment in another clinical study within the 30 days prior to commencing study treatment or having side effects of a prior study drug that are not recovered to grade ≤ 1 or baseline, except for alopecia~7. Concurrent chronic systemic immunotherapy, chemotherapy or hormone therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed and Carboplatin plus L-DOS47 (Type: EXPERIMENTAL): Patients will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort for the first and last two dosing cohorts, and a minimum of 1 and a maximum of 2 patients for the middle three dosing cohorts. The starting dose of L-DOS47 will be 0.59 µg/kg; further planned dose levels to be assessed are 0.78, 1.5, 3.0, 6.0, 9.0 and 12.0 µg/kg. The standard of care doses of pemetrexed \[500 mg/m2\] and carboplatin \[AUC6\], respectively, to be administered in combination with L-DOS47, will remain constant across cohorts.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years of age~* Symptomatic VMA, VMT, or macular hole~* BCVA 20/30 - CF 3' Snellen equivalent~* Willing and able to provide signed informed consent and willing to undertake all scheduled study-related assessments, visits, and treatments~* JETREA® treatment naïve~Exclusion Criteria:~* Patients who are pregnant, planning to become pregnant, or breastfeeding a child~* Uncontrolled ocular hypertension or glaucoma in study (defined as IOP ≥ 25mm Hg or a cup to disc ratio (CDR) \> 0.8 despite treatment with anti-glaucoma medication)~* Active malignancies within the last 12 months except appropriately treated carcinoma in situ of the crevices, melanoma, and prostate cancers treated with a curative intent~* Inability to comply with study or follow-up procedures~* Women who may become pregnant or lactating or intend to become pregnant during the study~* Known drug allergy to ocriplasmin or eplerenone~* Patients with known contraindications Eplerenone as outlined in the package insert

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: EXPERIMENTAL): Eplerenone
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Biopsy proven classical Hodgkin lymphoma. Classical Hodgkin lymphoma includes the subtypes of nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted, and classical Hodgkin lymphoma unspecified~* Advanced stage (Stage III or IV) disease~* Measurable disease on cross sectional imaging~* ECOG Performance Status 0-2~* Adequate blood counts and organ function~Exclusion Criteria:~* Pregnant or lactating women~* Laboratory Parameters as outlined in the protocol~* LV ejection fraction lower than normal as assessed by echocardiogram or MUGA scan~* DLCO less than 60% as measured by pulmonary function tests~* Prior history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for over one year~* Current or recent (within 4 weeks of the first infusion of this study) participation in an experimental drug study~* Life expectancy of less than 12 weeks~* Inability to comply with study procedures~* Inability to give informed consent~* Inadequately controlled hypertension~* Any prior history of hypertensive crisis or hypertensive encephalopathy~* NYHA Grade II or greater congestive heart failure~* History of myocardial infarction or unstable angina within 6 months prior to study enrollment~* History of stroke or transient ischemic attack within 6 months prior to study enrollment~* Known CNS involvement of Hodgkin lymphoma~* Significant vascular disease~* Symptomatic peripheral vascular disease~* Evidence of bleeding diatheses or coagulopathy~* Use of daily anticoagulant medications including warfarin, heparins, or aspirin \>325mg daily~* Major surgical procedure or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study~* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days of study enrollment~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment~* Serious, non-healing wound, ulcer, or bone fracture~* Proteinuria at screening~* Known hypersensitivity to any component of bevacizumab~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avastin (Bevacizumab) (Type: OTHER): single-arm, open-label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dorsal vs. Ventral Buccal Graft Dorsal vs. Ventral Buccal Graft

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Strictures must predominantly include the proximal and/or mid bulbar urethra and be otherwise amenable to buccal graft onlay urethroplasty~* Strictures may extend from the mid-bulbar urethra up to the distal bulbar urethra within the scrotum, but not through the scrotum to the pendulous junction~* Subjects able to consent for themselves~Exclusion Criteria:~* prior open urethral surgery, such as prior urethroplasty, artificial urinary sphincter placement, male urethral sling placement, and rectourethral fistula~* radiation therapy to the pelvis~* previous hypospadias repair~* lichen sclerosis unable to consent for themselves

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Urethroplasty with buccal mucosa graft (Type: EXPERIMENTAL): Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the dorsal wall of the urethra.
- Ventral Buccal (Type: ACTIVE_COMPARATOR): Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With CPAP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient admitted to the Clinical Physiology Department of Exercise of the Saint Etienne University Hospital (myocardial infarction, coronary stenting or coronary artery bypass) and referred for care in cardiac rehabilitation~* A native French speaker~* No daytime sleepiness (ESS \<or = 10)~* Signature of informed consent by the patient~Exclusion Criteria:~* Patients with a previous diagnosis of sleep apnea syndrome~* Patients with severe heart failure (stage III and IV of the NYHA)~* Patients with a neurodegenerative disease or other known cognitive disorders~* Presence of progressive disease other than coronary artery disease (cancer for example)~* Patients participating in other research that can change their cognitive function or drowsiness

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Patients treated (Type: EXPERIMENTAL): Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an Epworth sleepiness score (ESS) \<10. After randomization, they will be treated with CPAP treatment.
- Patients non-treated (Type: NO_INTERVENTION): Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an ESS \<10. After randomization, they will be not treated.
- Control group (Type: NO_INTERVENTION): Patients with CAD but without SAS (AHI\<15).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Clinical Feasibility of the New Indwelling Provox Vega 20 Voice Prosthesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* total laryngectomy~* use Provox2 voice prosthesis~* at least two prior prosthesis changes~Exclusion Criteria:~* current puncture problems (f. ex. infection)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early feasability arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RHAPSody: Diagnostic Utility of RUSH Following ROSC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Incoming ER patients with return of spontaneous circulation after cardiac arrest~Exclusion Criteria:~* Patients who do not achieve return of spontaneous circulation long enough for the exam to be performed~* Patients who have initial cardiac arrest while on an inpatient unit of the hospital

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ROSC RUSH Exam (Type: None): The study population will include out of hospital cardiac arrest (both traumatic and non-traumatic causes) with return of spontaneous circulation after the cardiac arrest while in the emergency department .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Chronic Hypoxia on Oxidative Phenotype in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD confirmed according to GOLD score.~* Hypoxemia group: resting arterial paO2 \<55 mmHg.~* Normoxemia group : resting arterial paO2 \> 67 mmHg~Exclusion Criteria:~* Unstable cardiorespiratory status (acute respiratory failure)~* Oxygen treatment started~* Inclusion in a pulmonary rehabilitation program in the last 6 months~* Anticoagulant treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COPD patients with chronic hypoxemia (Type: None): COPD patients with chronic and severe arterial hypoxemia at rest (paO2\<55mmHg).
- COPD patients with normoxia (Type: None): COPD patients with normoxia at rest (paO2\>67mmHg), matched for age, sex, bronchial obstruction and lean mass.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy